<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Healthcare Professionals Archives - Multiple Chronic Conditions</title>
	<atom:link href="https://multiplechronicconditions.org/category/healthcare-professionals/feed/" rel="self" type="application/rss+xml" />
	<link>https://multiplechronicconditions.org/category/healthcare-professionals/</link>
	<description>FREE resources to educate, update and promote best practices that ensure optimal patient-centered outcomes.</description>
	<lastBuildDate>Wed, 04 Feb 2026 14:51:43 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://multiplechronicconditions.org/wp-content/uploads/2024/03/mcc-icon-150x150.png</url>
	<title>Healthcare Professionals Archives - Multiple Chronic Conditions</title>
	<link>https://multiplechronicconditions.org/category/healthcare-professionals/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>American Diabetes Association Institute of Learning Free Continuing Education Modules</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/american-diabetes-association-institute-of-learning-free-continuing-education-modules/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Wed, 04 Feb 2026 14:50:48 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4126</guid>

					<description><![CDATA[<p>Since 1940, the American Diabetes Association® has been a trusted source for cutting-edge diabetes care education solutions. Our Institute of Learning offers 70+ free continuing education courses, webinars, and more to help you stay ahead of the curve.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/american-diabetes-association-institute-of-learning-free-continuing-education-modules/">American Diabetes Association Institute of Learning Free Continuing Education Modules</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Since 1940, the American Diabetes Association® has been a trusted source for cutting-edge diabetes care education solutions. Our Institute of Learning offers 70+ free continuing education courses, webinars, and more to help you stay ahead of the curve.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/american-diabetes-association-institute-of-learning-free-continuing-education-modules/">American Diabetes Association Institute of Learning Free Continuing Education Modules</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/2026-guideline-for-the-early-management-of-patients-with-acute-ischemic-stroke-a-guideline-from-the-american-heart-association-american-stroke-association/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Wed, 28 Jan 2026 14:10:00 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4124</guid>

					<description><![CDATA[<p>The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in evidence. This updated guideline is intended to provide a comprehensive, up-to-date, evidence-based set of recommendations, advising management from prehospital evaluation through acute treatment...</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/2026-guideline-for-the-early-management-of-patients-with-acute-ischemic-stroke-a-guideline-from-the-american-heart-association-american-stroke-association/">2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in evidence. This updated guideline is intended to provide a comprehensive, up-to-date, evidence-based set of recommendations, advising management from prehospital evaluation through acute treatment and early in-hospital management of complications and initiation of early secondary prevention measures. </p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/2026-guideline-for-the-early-management-of-patients-with-acute-ischemic-stroke-a-guideline-from-the-american-heart-association-american-stroke-association/">2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>2026 Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/2026-updated-version-of-its-global-strategy-for-prevention-diagnosis-and-management-of-chronic-obstructive-pulmonary-disease/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 15:26:53 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4114</guid>

					<description><![CDATA[<p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the 2026 updated version of its Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/2026-updated-version-of-its-global-strategy-for-prevention-diagnosis-and-management-of-chronic-obstructive-pulmonary-disease/">2026 Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released the 2026 updated version of its Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/2026-updated-version-of-its-global-strategy-for-prevention-diagnosis-and-management-of-chronic-obstructive-pulmonary-disease/">2026 Global Strategy for Prevention, Diagnosis and Management of Chronic Obstructive Pulmonary Disease</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/world-health-organization-guideline-on-the-use-and-indications-of-glucagon-like-peptide-1-therapies-for-the-treatment-of-obesity-in-adults/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 15:20:49 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4112</guid>

					<description><![CDATA[<p>Obesity as a global public health issue is a relatively recent but growing problem for all countries. Obesity arises from a set of complex interactions in individuals including genetics, neurobiology, and eating behaviors, as well as obesogenic environments resulting from shifts in diet, activity, and lifestyle alongside globalization and industrialization of food production and marketing.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/world-health-organization-guideline-on-the-use-and-indications-of-glucagon-like-peptide-1-therapies-for-the-treatment-of-obesity-in-adults/">World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Obesity as a global public health issue is a relatively recent but growing problem for all countries. Obesity arises from a set of complex interactions in individuals including genetics, neurobiology, and eating behaviors, as well as obesogenic environments resulting from shifts in diet, activity, and lifestyle alongside globalization and industrialization of food production and marketing.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/world-health-organization-guideline-on-the-use-and-indications-of-glucagon-like-peptide-1-therapies-for-the-treatment-of-obesity-in-adults/">World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/decision-making-and-downstream-outcomes-of-the-gabapentinoid-diuretic-prescribing-cascade/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Fri, 12 Dec 2025 15:20:06 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4110</guid>

					<description><![CDATA[<p>Prescribing cascades are an underrecognized driver of polypharmacy among older adults (aged ≥65 years). The clinical decision-making processes underlying cascades and their downstream consequences are poorly understood. This small study shows how providers may believe they are treating edema or heart failure – when it could be ongoing Gabapentinoid-Diuretic Prescribing Cascade</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/decision-making-and-downstream-outcomes-of-the-gabapentinoid-diuretic-prescribing-cascade/">Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Prescribing cascades are an underrecognized driver of polypharmacy among older adults (aged ≥65 years). The clinical decision-making processes underlying cascades and their downstream consequences are poorly understood. This small study shows how providers may believe they are treating edema or heart failure – when it could be ongoing <strong>Gabapentinoid-Diuretic Prescribing Cascade</strong></p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/decision-making-and-downstream-outcomes-of-the-gabapentinoid-diuretic-prescribing-cascade/">Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Primary Care Collaborative just released yesterday: Closing the Distance in Rural Primary Care.</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/primary-care-collaborative-just-released-yesterday-closing-the-distance-in-rural-primary-care/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Thu, 13 Nov 2025 15:18:11 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4105</guid>

					<description><![CDATA[<p>Rural health care in the U.S. is struggling with headwinds, including aging populations, a shrinking physician workforce and consolidation of health care services. Some rural communities can access major health systems by interstate travel, while others are isolated by many miles, mountains and rough terrain, and lack adequate broadband and emergency services. When a rural...</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/primary-care-collaborative-just-released-yesterday-closing-the-distance-in-rural-primary-care/">Primary Care Collaborative just released yesterday: Closing the Distance in Rural Primary Care.</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Rural health care in the U.S. is struggling with headwinds, including aging populations, a shrinking physician workforce and consolidation of health care services. Some rural communities can access major health systems by interstate travel, while others are isolated by many miles, mountains and rough terrain, and lack adequate broadband and emergency services. When a rural hospital closes, it is an economic blow to a community as well as a blow to local health care access.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/primary-care-collaborative-just-released-yesterday-closing-the-distance-in-rural-primary-care/">Primary Care Collaborative just released yesterday: Closing the Distance in Rural Primary Care.</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Thu, 06 Nov 2025 14:41:39 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4099</guid>

					<description><![CDATA[<p>Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published up until 31 March 2025.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias/">2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).  This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published up until 31 March 2025.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias/">2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/asn-kidney-health-guidance-on-potassium-and-phosphorus-food-additives/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Fri, 31 Oct 2025 18:04:41 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4097</guid>

					<description><![CDATA[<p>Diet is a cornerstone of preventing and managing kidney diseases. As kidney disease progresses, the loss of homeostasis places individuals with CKD at higher risk for hyperkalemia and hyperphosphatemia. These mineral and electrolyte alterations are among multiple key targets of nutritional management, as they can result in adverse clinical outcomes.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/asn-kidney-health-guidance-on-potassium-and-phosphorus-food-additives/">ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>Diet is a cornerstone of preventing and managing kidney diseases. As kidney disease progresses, the loss of homeostasis places individuals with CKD at higher risk for hyperkalemia and hyperphosphatemia. These mineral and electrolyte alterations are among multiple key targets of nutritional management, as they can result in adverse clinical outcomes.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/asn-kidney-health-guidance-on-potassium-and-phosphorus-food-additives/">ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Acupuncture treatment improves disabling effects of chronic low back pain in older adults</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/acupuncture-treatment-improves-disabling-effects-of-chronic-low-back-pain-in-older-adults/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Mon, 15 Sep 2025 13:48:22 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4082</guid>

					<description><![CDATA[<p>According to a study funded by the National Institutes of Health (NIH), older Americans with chronic low back pain who received acupuncture had greater improvement in physical function and reduced pain than those who received usual medical care only, generally prescribed medications or physical therapy. Chronic low back pain is the leading cause of disability...</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/acupuncture-treatment-improves-disabling-effects-of-chronic-low-back-pain-in-older-adults/">Acupuncture treatment improves disabling effects of chronic low back pain in older adults</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>According to a study funded by the National Institutes of Health (NIH), older Americans with chronic low back pain who received acupuncture had greater improvement in physical function and reduced pain than those who received usual medical care only, generally prescribed medications or physical therapy. Chronic low back pain is the leading cause of disability worldwide and affects over one-third of older adults in the United States. Treatment options range from pain-relieving drugs to complementary therapies, including acupuncture. There is an urgent need for safe, effective, and non-addictive pain management approaches.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/acupuncture-treatment-improves-disabling-effects-of-chronic-low-back-pain-in-older-adults/">Acupuncture treatment improves disabling effects of chronic low back pain in older adults</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs</title>
		<link>https://multiplechronicconditions.org/healthcare-professionals/new-guideline-puts-some-at-the-front-of-the-line-for-glp-1-sglt2-drugs/</link>
		
		<dc:creator><![CDATA[Michelle]]></dc:creator>
		<pubDate>Fri, 22 Aug 2025 14:32:46 +0000</pubDate>
				<category><![CDATA[Healthcare Professionals]]></category>
		<guid isPermaLink="false">https://multiplechronicconditions.org/?p=4073</guid>

					<description><![CDATA[<p>In a new &#8220;living&#8221; guideline, intended to keep pace with the rapidly growing evidence base for these emerging drugs, an international expert group said that SGLT2 inhibitors and GLP-1 receptor agonists both get a weak recommendation against use in type 2 diabetes patients at low risk of cardiovascular and kidney complications, defined as three or...</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/new-guideline-puts-some-at-the-front-of-the-line-for-glp-1-sglt2-drugs/">New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>In a new &#8220;living&#8221; guideline, intended to keep pace with the rapidly growing evidence base for these emerging drugs, an international expert group said that SGLT2 inhibitors and GLP-1 receptor agonists both get a weak recommendation against use in type 2 diabetes patients at low risk of cardiovascular and kidney complications, defined as three or fewer cardiovascular risk factors.</p>
<p>The post <a href="https://multiplechronicconditions.org/healthcare-professionals/new-guideline-puts-some-at-the-front-of-the-line-for-glp-1-sglt2-drugs/">New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs</a> appeared first on <a href="https://multiplechronicconditions.org">Multiple Chronic Conditions</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
